P. falciparum ACPRs were 97.8 % and 100.0 % in artemether-lumefantrine and artemisinin-naphthoquine-treated patients , respectively ( difference 2.2 % [ 95 % CI -3.0 % to 8.4 % ] versus -5.0 % non-inferiority margin , p = 0.24 ) , and P. vivax ACPRs were 30.0 % and 100.0 % , respectively ( difference 70.0 % [ 95 % CI 40.9 % -87.2 % ] , p < 0.001 ) .